Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing
Benjamin M. Manning(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Robyn T. Sussman(University of Pennsylvania), James K. Mangan(UC San Diego Health System), Jennifer J.D. Morrissette(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Alexander E. Perl(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), David L. Porter(Chapman University), Shannon R. McCurdy(Hospital of the University of Pennsylvania), Safoora Deihimi(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Mary Ellen Martin(University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Selina M. Luger(University of Pennsylvania)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907